

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA rimegepant for treating or preventing migraine
[ID1539]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During the scoping process the British Association for the Study of Headache (BASH) highlighted migraine affects women nearly three times more than men and migraine is more common in people aged 18 to 45 years.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

The difference in prevalence of migraine between men and women is not expected to be an equality issue that can be addressed in a technology appraisal.

The committee will appraise rimegepant for the population in its marketing authorisation.

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

Approved by Associate Director (name): ...Linda Landells...

Date: 5 August 2021